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Abstract
Background: We investigate whether non–high-density lipoprotein cholesterol (non-HDL-C) provides a better
estimate of cardiovascular risk than other lipid profiles in normotensive and euglycemic middle-aged and elderly
adults.
Methods: A total of 512 males and 958 females were enrolled from the Changfeng Study. A standard interview,
anthropometric measurements and laboratory analyses were performed for each participant. Bilateral carotid intima-
media thicknesses (CIMTs) were measured using ultrasonography, and the presence of carotid plaques was assessed.
Results: The mean values of non-HDL-C were 3.4 ± 0.8 mmol/l and 3.6 ± 0.9 mmol/l for male and female subjects,
respectively. Compared with female subjects with non-HDL-C in the first quartile, female subjects with non-HDL-C in
the fourth quartile had 1.317-fold increased risks for carotid plaques after adjusting for conventional cardiovascular
disease (CVD) risk factors and increasing quartiles of all lipid levels. Non-HDL-C was positively associated with the CIMT
after adjusting for CVD risk factors in female subjects (β = 0.062, P = 0.034).
Conclusions: These results suggest that non-HDL-C is independently associated with carotid atherosclerosis in
normotensive and euglycemic females.
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Background
Lipoprotein abnormalities play a role in the accelerated
atherosclerosis. Although low-density lipoprotein choles-
terol (LDL-C) has been the primary measure used to es-
timate cardiovascular disease (CVD) risk by guidelines
for over 3 decades, there are now many studies demon-
strating consistent outperformance by non–high-density
lipoprotein cholesterol (non-HDL-C) [1, 2]. Moreover,
recommendations from the International Atherosclerosis
Society Expert Dyslipidemia Panel [3] and the National
Lipid Association [4] recommend non-HDL-C also as a
primary target of therapy. Non-HDL-C, which repre-
sents the total cholesterol content of apolipoprotein B
(apo-B) containing lipoproteins, is particularly useful in
risk assessment for diabetic patients rather than LDL-C
levels [5]. Non–HDL-C is a quick and simple calculation
of total cholesterol (TC) minus high-density lipoprotein
cholesterol (HDL-C), and can be obtained in the non-
fasting state without affecting results. In studies, re-
searchers have shown that non-HDL-C is a better
marker of coronary heart disease (CHD) risk than LDL-
C in patients with CVD and diabetes [6, 7]. In the
Strong Heart Study, Lu et al. [8] found non-HDL-C to
be a better predictor of cardiovascular events in patients
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with diabetes compared to LDL-C [hazard ratio (HR)
2.23 and 1.80 for the highest tertile of non-HDL-C
among men and women, respectively]. In diabetic men
of the Health Professionals’ Follow-up Study, compari-
sons of nested models highlighted that non-HDL-C add
significantly to the prediction of CVD risk beyond LDL-
C [9]. Tohidi et al demonstrated that among the non-
diabetic population, non-HDL-C was a significant pre-
dictor of incident CVD in both genders; similar to the
association shown among non-diabetic Arab community
[10]. However, the Rancho Bernardo Study of 1386
women and 1094 men (mean age, 69 years) found that
non-HDL-C was not superior to individual lipids, lipo-
proteins, or their ratios in the prediction of fatal CHD
and CVD in a 10 year follow-up [11]. As shown by pre-
vious reports, non-HDL-C may be associated with the
prognostic factors of CVD, such as diabetes [12] and
hypertension [13], which may themselves affect CVD
events. Therefore, the relationship between non-HDL-C
and atherosclerosis may be confounded by the presence
of hyperglycemia and hypertension. In addition, it has
been shown that non-HDL-C values vary between differ-
ent ethnicities. The above large scale studies were mostly
confined to the individuals in Europe and North America,
which could not reflect the features of other ethnicities.
Few studies have directly compared the relative usefulness
of conventional lipid particles for prediction of subclinical
atherosclerosis in the Chinese population. Given the risk
for CVD in Chinese middle-aged and elderly adults [14],
more evidence is needed to evaluate the association be-
tween non-HDL-C and atherosclerosis.
Accordingly, in this study we aim to compare the
association of non-HDL-C, LDL-C, HDL-C and TC with
carotid intima-media thickness (CIMT) and carotid
plaque, reliable markers of the severity of atherosclerosis
[15] in Chinese middle-aged and elderly adults with




The subjects were participants in the Changfeng
Study, a community-based study of chronic diseases
among middle-aged and elderly individuals which has
been described elsewhere [16, 17]. From June 2009 to
June 2012, 5485 participants were initially enrolled.
We excluded 4015 participants for the following reasons:
lack of physical examination and laboratory assessments
(n = 110), prevalent CVD (myocardial infarction, stroke,
or) (n = 404), prevalent hemodialysis (n = 2), prevalent
hypertension (systolic blood pressure ≥ 140 mmHg,
diastolic blood pressure ≥90 mmHg, the use of anti-
hypertensive medications, or diagnosed hypertension)
(n = 2672), prevalent diabetes or pre-diabetes (fasting
glucose ≥5.6 mmol/L, OGTT (oral glucose tolerance test)
2 h glucose ≥7.8 mmol/L, the use of hypoglycemic medi-
cation, or diagnosed diabetes) (n = 812), triglycerides
≥4.5 mmol/L or the use of lipid-lowering therapy (n = 12),
and use of the antiplatelet agents (n = 3). Finally, 1470
subjects (512 males and 958 females) were included in the
analysis.
Ethics statement
The study was approved by the ethical committee of
Zhongshan Hospital, Fudan University and was conducted
in accordance with the guidelines of the Declaration of
Helsinki. Written informed consent was obtained from all
participants.
Measurements
Interviews, physical examinations and ultrasound scans
were performed at the Changfeng Community Health
Service Center. Trained nurses interviewed the partici-
pants and obtained their medical history and lifestyle.
Weight and height were measured while the participant
was clothed in a light gown. The waist circumference
was measured midway between the lowest rib margin
and the iliac crest in a standing position. The hip cir-
cumference was measured at the widest level over the
greater trochanters. The waist-to-hip ratio (WHR) was
calculated from these values. The body mass index
(BMI) was calculated as the weight divided by the height
squared (kg/m2). The resting blood pressure was mea-
sured 3 times, and the mean value was used for the ana-
lysis. Blood samples were obtained after a fasting period
of at least 10 h. TC, HDL-C and triglycerides (TG) were
measured using a model 7600 automated bio-analyser
(Hitachi, Tokyo, Japan). The level of LDL-C was calcu-
lated using the Friedewald equation. Non-HDL-C is cal-
culated as TC minus HDL-C [7]. The fasting blood
glucose (FBG) and 2 h glucose levels following a 75 g
oral glucose challenge (PPG) (postprandial blood glu-
cose) for non-diabetics were measured using the glucose
oxidase method. Serum insulin was measured using
electrochemiluminescence immunoassay using an im-
munoassay analyzer (Roche Cobas-6001, Switzerland)
(coefficient of variation <5.0%). Homeostasis model as-
sessment index for insulin resistance (HOMA-IR) and
beta cell function (HOMA-B%) were used to estimate
insulin sensitivity and insulin secretion [18].
Carotid ultrasonography was performed (using a GE
Logic P5 (GE Healthcare, Milwaukee, USA) scanner with
a 10-MHz probe) on all participants by an experienced
radiologist who was blinded to the participants’ details.
Right and left CIMT were measured in the common ca-
rotid artery approximately 1 cm proximal to the bifur-
cation at the far wall during end diastole. The CIMT
was quantified at plaque-free sections of the carotid
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arteries as the distance between the lumen-intima and
media-adventitia interfaces. Three values were measured
on each side, and the average CIMT was used for the
analysis. Carotid plaque was defined as the presence
of focal wall thickening resulting in a thickness that
is ≥ 50% greater than that of the surrounding vessel
wall or as a focal region with a CIMT greater than
1.5 mm that protrudes into the lumen that is distinct
from the adjacent boundary, according to American
Society of Echocardiography [19]. The near and far
walls of bilateral common carotid arteries, the carotid
bifurcation, and the internal carotid artery were
scanned for the presence of plaques. Repeated mea-
surements on the same subjects (performed in 103
subjects) yielded an intraclass correlation coefficient
of 0.93 (95% confidence interval, 0.91 to 0.96).
Hypertension was defined according to the Seventh
Report of the Joint National Committee [20]. Glucose
tolerance was evaluated based on OGTT as set by the
American Diabetes Association 2010 criteria [21]. The
diagnosis of dyslipidaemia was based on Chinese guide-
lines for the prevention and treatment of dyslipidaemia
in adults [22]. The diagnosis of CVD and peripheral vas-
cular disease (PAD) was based on self-reports and con-
firmed using medical records.
Statistical analyses
The data were expressed as the means ± SD, frequencies
or medians with 25th and 75th percentiles. Skewed vari-
ables were logarithmically transformed to improve nor-
mality prior to analysis. Association between increasing
quartile of lipid values and carotid atherosclerosis was
initially assessed with a chi-square analysis, stratified by
gender. Linear regression analysis was performed to
examine the association between the lipid profiles and
the CIMT. Logistic regression was then employed to fur-
ther quantify the association between lipid level quartiles
and carotid plaque, with the lowest quartile as reference.
The multivariate regression analysis was adjusted, as fol-
lows: model 1: age, SBP, DBP, FBG, PPG, BMI, WHR,
smoking (yes or no), HOMA-IR and HOMA-B%. In
model 2, we adjusted for all lipid variables in addition to
risk factors in model 1 to assess the independent associ-
ation of each lipid profile with carotid atherosclerosis.
Odds ratios (ORs) were calculated for a 1-unit increase
in the lipid profiles. SPSS 16.0 for Windows (SPSS 16.0
Inc, USA) was used to perform the statistical analyses.




A total of 512 males and 958 females were evaluated.
The demographic and clinical characteristics of the
study subjects are shown in Table 1. The mean values of
CIMT were 0.746 ± 0.142 mm and 0.694 ± 0.119 mm in
males and females, respectively. The prevalence of ca-
rotid plaques was 27.0% and 14.4%. The mean values of
non-HDL-C were 3.4 ± 0.8 mmol/l and 3.6 ± 0.9 mmol/l.
A total of 21.6% of the subjects were current smokers.
The differences between genders in terms of age, BMI,
WHR, SBP, DBP, TC, LDL-C, HDL-C, non-HDL-C,
smoking, HOMA-IR, HOMA-B%, CIMT, and the pres-
ence of carotid plaques were statistically significant.
The mean lipid values were well within the recom-
mended range by the guidelines of Joint Committee for
Developing Chinese guidelines on Prevention and Treat-
ment of Dyslipidemia in Adults [22]. The majority of the
study population (n = 1082, 73.6%) had LDL-C levels
<3.37 mmol/l, whereas 36.6% (n = 538) had LDL-C
<2.6 mmol/l. Only 1.4% (n = 20) of participants had
LDL-C ≥ 4.9 mmol/l. Low HDL-C (<1.04 mmol/l was
observed in 113 cases (7.7%) of the study population.
Association of carotid plaque and lipid levels
Figure 1 shows the prevalence of carotid plaque accord-
ing to increasing quartiles of lipid levels. The presence
of carotid plaque increased significantly across increas-
ing quartiles of TC level in the male subjects, whereas
prevalence increased significantly across increasing quar-
tiles of TC, LDL-C and non-HDL-C levels in the female
subjects. The highest chi-square value was observed for
the relationship of non-HDL-C levels in the prevalence
of carotid plaque (chi-square = 9.18) in females.
In a multivariate model adjusting for age, BMI,
WHR, FBG, PPG, SBP, DBP, smoking, logHOMA-IR
and logHOMA-B%, male subjects with TC and non-
HDL-C in the fourth quartiles had 2.213-fold and
2.149-fold increased risks for carotid plaques relative
to those in the lowest quartiles (Table 2, model 1). In
the meanwhile, female subjects with TC and non-
HDL-C in the fourth quartiles had 1.786-fold and
1.590-fold increased risks (Table 2, model 1). After
simultaneously controlling for increasing quartiles of
all lipid levels (Table 2, model 2), only females with
non-HDL-C in the fourth quartiles had 1.317-fold in-
creased risks for carotid plaques relative to those in
the lowest quartiles. On the other hand, no such as-
sociation was seen with TC, LDL-C and HDL-C.
Association of CIMT and non-HDL-C levels
The multiple linear regression revealed that the non-
HDL-C was positively correlated with the CIMT after
adjusting for traditional CVD risk factors including age,
BMI, WHR, FBG, PPG, SBP, DBP, TC, LDL-C, HDL-C,
smoking, logHOMA-IR and logHOMA-B% in female
subjects (Table 3). However, no such association existed
in male subjects (Table 3).
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Discussion
Our study showed that non-HDL-C was independently
associated with carotid atherosclerosis in a normotensive
and euglycemic female population. The CIMT and the
prevalence of carotid plaques significantly increased with
increasing non-HDL-C after adjusting for conventional
CVD risk factors and all lipid levels in female subjects.
However, no relationship was found between non-HDL-
C and carotid atherosclerosis in male subjects.
Non-HDL-C has recently become a more and more
important topic in cardiovascular research [1–3]. Non-
HDL-C reflects the number of atherogenic particles
present in the plasma. This includes very low density li-
poproteins (VLDL), intermediate density lipoproteins
(IDL) and LDL. Although a number of studies have
demonstrated that non-HDL-C activity is associated
with the development of cardiovascular events [1–5], it
is still debated whether non-HDL-C provides a better es-
timate of cardiovascular risk than other lipid profiles.
The participants in the Strong Heart Study [8] and the
Health Professionals’ Follow-up Study [9] were diabetic
patients. Although Tohidi’s study [10] was conducted
using nondiabetic participants, these studies excluded only
subjects with fasting blood glucose levels ≥7.0 mmol/L,
2 h plasma glucose ≥ 11.1 mmol/L, or subjects who were
using hypoglycaemic medications. Therefore, the results
may be confounded by the inclusion of subjects with im-
paired glucose regulation or postprandial hyperglycemia.
Moreover, the previous studies enrolled study populations
with different proportions of hypertension. As noted, re-
cent studies have demonstrated that there was a close as-
sociation between non-HDL-C and cardiovascular risk
factors, such as hyperglycemia and hypertension [12, 13].
Therefore, the relationship between carotid atherosclerosis
and non-HDL-C would be affected by the chronic effects
of CVD risk factors. The impact of residual confounding
factors would remain after adjusting for CVD risk factors
in previous studies. To exterminate the various effects of
CVD risk factors on the relationship between carotid ath-
erosclerosis and non-HDL-C, we explored the relationship
in the subjects with normal blood pressure and NGT.
Thus, the association between non-HDL-C and carotid
atherosclerosis was not confounded.
Non-HDL-C is the sum of the masses of cholesterol in
the atherogenic apoB lipoprotein particles. In of principle,
non–HDL-C represents a broader, more inclusive meas-
ure of atherogenic risk. Atherogenic dyslipidemia consists
of the combination of an increase in VLDL, with a reduc-
tion of levels of HDL-C, also accompanied by a high pro-
portion of small and dense LDL particles [4]. Atherogenic
dyslipidemia is considered the main cause of the residual
risk of experiencing cardiovascular disease (CVD), which
Table 1 Characteristics of the study subjects
Variables All Male subjects Female subjects P value between
gendersn = 1470 n = 512 n = 958
Age (ys) 57.7 (8.1) 59.0 (8.3) 57.0 (8.0) <0.001
BMI (kg/m2) 22.9 (2.9) 23.1 (3.0) 22.7 (2.9) 0.029
WHR 0.868 (0.069) 0.901 (0.069) 0.850 (0.061) <0.001
Current smoker, n (%) 317 (21.6%) 296 (57.8%) 21 (2.2) <0.001
SBP (mmHg) 120.4 (11.1) 121.8 (11.2) 119.6 (11.0) <0.001
DBP (mmHg) 71.5 (7.7) 73.1 (7.8) 70.7 (7.5) <0.001
TC (mmol/L) 5.0 (0.9) 4.8 (0.9) 5.2 (0.9) <0.001
LDL cholesterol (mmol/L) 2.9 (0.8) 2.8 (0.7) 3.0 (0.8) <0.001
HDL cholesterol (mmol/L) 1.5 (0.4) 1.4 (0.4) 1.6 (0.4) <0.001
Non-HDL-C (mmol/L) 3.5 (0.9) 3.4 (0.8) 3.6 (0.9) <0.001
TG (mmol/L) 1.3 (0.6) 1.4 (0.7) 1.3 (0.6) 0.167
FBG (mmol/L) 4.9 (0.4) 4.9 (0.4) 4.9 (0.3) 0.608
PPG (mmol/L) 5.6 (1.1) 5.6 (1.2) 5.6 (1.1) 0.391
HOMA-IR 1.4 (0.9–1.9) 1.2 (0.8–1.8) 1.4 (1.0–1.9) <0.001
HOMA-B% 93.3 (67.0–126.2) 83.9 (58.2–123.4) 97.3 (71.7–128.9) <0.001
CIMT (mm) 0.712 (0.130) 0.746 (0.142) 0.694 (0.119) <0.001
Carotid plaque (n,%) 276 (18.8%) 138 (27.0%) 138 (14.4%) <0.001
Data are mean (SD) or percentage of subjects or median (interquartile range)
BMI body mass index, WHR waist-hip-ratio, FBG fasting blood glucose, PPG OGTT 2 h blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure, TC
total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, Non-HDL-C non high density lipoprotein
cholesterol, HOMA-IR homeostasis model assessment index for insulin resistance, HOMA-B homeostasis model assessment index for beta cell function
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is still presented by any patient on treatment with statins
despite maintaining LDL-C levels below the values
considered to be the objective [23]. The finding sug-
gests opportunities for further risk reduction of CVD.
Emerging research has identified potential surrogate
lipid markers for assessing cardiovascular risk, includ-
ing non–HDL-C. The dynamic flux of lipoproteins be-
tween subtypes under direction of lipoprotein lipase
(LPL) and cholesterol ester transfer protein (CETP) makes
direct assessment of total atherogenic burden a challenge,
which is significantly improved by non–HDL-C [24, 25].
Several years ago, non-HDL-C was highlighted as an
important secondary lipid therapeutic goal in the U.S.
National Cholesterol Education Program’s Adult Treat-
ment Panel [26]. The recent recommendations from the
International Atherosclerosis Society Expert Dyslipidemia
Panel [3] and the National Lipid Association [4] also
recommend non–HDL-C as a primary target of therapy.
Using non-HDL-C levels offers several practical advan-
tages over other traditional lipid parameters for routine
A
B
Fig. 1 a Prevalence of carotid plaque across quartile of lipid levels in male subjects. TC: 2.65–4.15mmol/L 1st quartile; 4.17–4.69mmol/L 2nd
quartile; 4.71–5.28mmol/L 3rd quartile; 5.29–8.84mmol/L 4th quartile. LDL-C: 1.05–2.27mmol/L 1st quartile; 2.28–2.69mmol/L 2nd quartile; 2.7–
3.23mmol/L 3rd quartile; 3.24–6.65mmol/L 4th quartile. HDL-C: 0.21–1.12mmol/L 1st quartile; 1.13–1.3mmol/L 2nd quartile; 1.31–1.55mmol/L 3rd
quartile; 1.56–4mmol/L 4th quartile. Non-HDL-C: 1.51–2.78mmol/L 1st quartile; 2.79–3.3mmol/L 2nd quartile; 3.31–3.94mmol/L 3rd quartile; 3.96–
7.87mmol/L 4th quartile. b Prevalence of carotid plaque across quartile of lipid levels in female subjects. TC: 3.07–4.62mmol/L 1st quartile; 4.63–
5.15mmol/L 2nd quartile; 5.16–5.73mmol/L 3rd quartile; 5.74–9.62mmol/L 4th quartile. LDL-C: 1.12–2.45mmol/L 1st quartile; 2.46–2.94mmol/L 2nd
quartile; 2.95–3.47mmol/L 3rd quartile; 3.48–6.81mmol/L 4th quartile. HDL-C: 0.5–1.33mmol/L 1st quartile; 1.34–1.57mmol/L 2nd quartile; 1.58–
1.85mmol/L 3rd quartile; 1.86–3.27mmol/L 4th quartile. Non-HDL-C: 1.45–2.98mmol/L 1st quartile; 2.99–3.56mmol/L 2nd quartile; 3.57–4.17mmol/L
3rd quartile; 4.18–8mmol/L 4th quartile
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Table 2 Adjusted odd ratios for carotid plaque according to lipid levels in male and female subjects
Male subjects
1 2 3 4 Trend across quartiles
TC
Model 1 1 (ref) 1.263 (0.680–2.374) 1.523 (0.827–2.807) 2.213 (1.199–4.084) 0.071
Model 2 1 (ref) 1.209 (0.550–2.502) 1.550 (0.543–4.422) 2.129 (0.507–8.944) 0.765
LDL-C
Model 1 1 (ref) 0.757 (0.408–1.402) 1.137 (0.627–2.062) 1.498 (0.827–2.711) 0.176
Model 2 1 (ref) 0.511 (0.253–1.030) 0.482 (0.182–1.278) 0.428 (0.117–1.560) 0.295
HDL-C
Model 1 1 (ref) 0.787 (0.427–1.451) 0.837 (0.444–1.581) 0.746 (0.305–1.197) 0.206
Model 2 1 (ref) 0.767 (0.408–1.443) 0.742 (0.369–1.490) 0.776 (0.326–1.183) 0.289
Non-HDL-C
Model 1 1 (ref) 1.178 (0.628–2.209) 1.302 (0.712–2.422) 2.149 (1.121–4.118) 0.069
Model 2 1 (ref) 1.322 (0.624–2.801) 1.606 (0.525–4.910) 2.657 (0.562–6.566) 0.209
Female subjects
1 2 3 4 Trend across quartiles
TC
Model 1 1 (ref) 1.141 (0.645–2.017) 1.301 (0.745–2.273) 1.786 (1.044–3.056) 0.142
Model 2 1 (ref) 1.149 (0.572–2.306) 1.312 (0.504–3.412) 1.795 (0.490–5.575) 0.787
LDL-C
Model 1 1 (ref) 0.915 (0.518–1.614) 1.165 (0.677–2.003) 1.615 (0.957–2.725) 0.128
Model 2 1 (ref) 0.834 (0.431–1.613) 1.015 (0.420–2.326) 1.209 (0.368–3.967) 0.735
HDL-C
Model 1 1 (ref) 0.866 (0.509–1.474) 1.184 (0.695–2.018) 0.987 (0.561–1.737) 0.716
Model 2 1 (ref) 0.776 (0.446–1.348) 1.051 (0.580–1.903) 0.878 (0.376–1.609) 0.616
Non-HDL-C
Model 1 1 (ref) 0.951 (0.539–1.679) 1.230 (0.853–1.957) 1.590 (1.034–2.708) 0.035
Model 2 1 (ref) 0.724 (0.457–1.469) 1.064 (0.942–1.776) 1.317 (1.019–2.511) 0.074
Model 1 adjusted for age, BMI, WHR, FBG, PPG, SBP, DBP, smoking, logHOMA-IR and logHOMA-B%, Model 2 adjusted for increasing quartiles of all the other lipid
levels in addition to the risk factors adjusted in Model 1
BMI body mass index, WHR waist-hip-ratio, FBG fasting blood glucose, PPG OGTT 2 h blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure,
TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, Non-HDL-C non high density lipoprotein cholesterol,
HOMA-IR homeostasis model assessment index for insulin resistance, HOMA-B homeostasis model assessment index for beta cell function
Table 3 Association of Non-HDL-C with CIMT by linear regression analysis
Male subjects Female subjects
β Standard β 95% CI P β Standard β 95% CI P
Unadjusted 0.008 0.050 0.006–0.023 0.263 0.016 0.114 0.007–0.024 <0.001
Model 1 0.004 0.031 0.003–0.021 0.319 0.011 0.075 0.004–0.020 0.010
Model 2 0.002 0.013 0.001–0.117 0.651 0.009 0.062 0.002–0.017 0.034
Dependent variable: CIMT; Independent variable: Non-HDL-C
β: regression coefficient. β was calculated for a 1-unit increase in Non-HDL-C
Model 1 adjusted for age, BMI, WHR, FBG, PPG, SBP, DBP, smoking, logHOMA-IR and logHOMA-B%, Model 2 adjusted for all the other lipid levels in addition to the
risk factors adjusted in Model 1
BMI body mass index, WHR waist-hip-ratio, FBG fasting blood glucose, PPG OGTT 2 h blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure,
TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, Non-HDL-C non high density lipoprotein cholesterol,
HOMA-IR homeostasis model assessment index for insulin resistance, HOMA-B homeostasis model assessment index for beta cell function, CIMT carotid
intima-media thickness
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clinical practice. First, measurement of the non–HDL-C
level has no additional cost or inconvenience because it
is easily calculated from the standard lipid profile with-
out the need for prior fasting. Second, non-HDL-C level
might also identify a group of individuals who have all of
the potentially atherogenic lipid fractions [LDL-C, lipo-
protein (a) [11], IDL-C [5] and VLDL-C remnants [5].
Finally, they can also be an exact marker in diabetic pa-
tients with hypertriglyceridemia, which can cause LDL-C
level calculations using the Friedewald formula to be po-
tentially inaccurate [3, 4]. In addition, the adoption of
non–HDL-C across all levels of triglycerides would sub-
stantially simplify implementation of clinical guidelines.
In the present study, we did not find the association
between non-HDL-C level and carotid atherosclerosis in
male as the previous studies reported [27, 28]. Our study
showed that non-HDL-C levels are better targets com-
pared with other lipid profiles in female subjects, which
presented as a stronger linear relationship with increased
CIMT and a more powerful discriminatory ability for
carotid plaque prediction. The results were in line with
another population-based study in America [29]. Mora
et al. found among initially healthy women, those with
LDL-C < 121 mg/dl (3.13 mmol/l), non-HDL-C was
more closely associated with coronary risk than LDL-C
[29]. The diversity may be due to the sex-related differ-
ences and ethnic differences in lipid level and athero-
sclerosis [30]. Additionally, the non-HDL-C levels of the
male subjects in this study were relatively lower in compari-
son with females, while ages, BMI, WHR, blood pressure,
and current smokers were higher, which may contribute to
the insignificant correlation between non-HDL-C and ca-
rotid atherosclerosis in males. However, we cannot further
elaborate on the reasons behind this phenomenon.
Thus, our results may have important clinical implica-
tions with adding non-HDL-C into the evaluation tools
for improving the detection of CVD among community
based female subjects. The American College of
Cardiology [6], American Diabetes Association [31] and
National Lipid Association [25] have already recom-
mended reporting non-HDL-C levels as part of routine
lipid panel results. In the context of patient care, screen-
ing based on the non-HDL-C would enable clinicians to
provide early interventions. An early evaluation of the
non-HDL-C would be advantageous for the early detec-
tion of CVD, and individuals with increased non-HDL-C
might benefit from more aggressive lifestyle modifica-
tions and dietary regimen.
Our study has limitations. It was a cross-sectional study,
so no conclusion about cause and effect can be made. Our
results reflect the relationship within the middle-aged and
elderly subjects, limiting our external validity. Indeed, using
the Friedwald formula there in an inherent risk of miscalcu-
lating the actual LDL-C levels, especially in the presence
of elevated TC. In our cohort there were no patients
with TC > 10.36 mmolL (400 mg/dl). The strengths of
the study were that it was conducted on a
population-based cohort. Additionally, we used both
CIMT and carotid plaques as the surrogate markers
of atherosclerosis [32].
Conclusions
In conclusion, our study shows that among the trad-
itional lipid measures, non-HDL-C was more strongly
associated with subclinical atherosclerosis as estimated
by measurement of CIMT and carotid plaque in
community based female subjects. The third Adult
Treatment Panel of the NCEP has recommended LDL-C
as the primary target of therapy and the use of non–
HDL-C as a secondary target of lipid lowering for indi-
viduals with TG concentrations ≥2.26 mmol/L (200 mg/
dL) [33]. However, many individuals are at increased risk
of CHD due to elevated concentrations of atherogenic li-
poproteins not reflected in LDL-C measurement. Our
results support the viewpoint that non–HDL-C may be
a potentially better marker in evaluating the cardiovas-
cular risk than LDL-C. The use of non-HDL-C instead
of LDL-C as a primary target for cholesterol lowering
therapy deserves further investigation.
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